Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNFT GENFIT	$4.06 -0.2%	$4.03	$2.55 ▼ $6.42	$203.51M	1.08	4,134 shs	3,532 shs
RAPT Rapt Therapeutics	$12.65 -9.3%	$8.75	$5.67 ▼ $27.84	$230.51M	-0.09	132,360 shs	73,688 shs
SXTC China SXT Pharmaceuticals	$1.62 -4.1%	$1.69	$0.95 ▼ $10.24	$196.09M	1.18	51,622 shs	228,544 shs
XCUR Exicure	$8.16 -2.6%	$8.30	$1.44 ▼ $36.00	$52.94M	3.57	283,582 shs	6,714 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNFT GENFIT	+4.92%	+2.51%	+4.09%	+8.07%	-5.68%
RAPT Rapt Therapeutics	+13.52%	+32.51%	+87.37%	+99.28%	-42.87%
SXTC China SXT Pharmaceuticals	-3.98%	+1.50%	-8.15%	+6.96%	-81.79%
XCUR Exicure	+5.41%	+28.13%	+28.92%	-24.78%	+1,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNFT GENFIT	2.2908 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.0
RAPT Rapt Therapeutics	4.1241 of 5 stars	3.1	4.0	4.2	1.7	1.7	0.6
SXTC China SXT Pharmaceuticals	0.4869 of 5 stars	0.0	5.0	0.0	0.0	0.0	0.6
XCUR Exicure	0.8917 of 5 stars	0.0	3.0	4.7	0.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNFT GENFIT	3.00	Buy	$13.00	220.20% Upside
RAPT Rapt Therapeutics	2.43	Hold	$21.67	71.28% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
XCUR Exicure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XCUR, RAPT, GNFT, and SXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNFT GENFIT	$76.77M	2.64	$0.07 per share	58.19	$1.50 per share	2.71
RAPT Rapt Therapeutics	$1.53M	136.75	N/A	N/A	$11.51 per share	1.10
SXTC China SXT Pharmaceuticals	$1.93M	97.39	N/A	N/A	$243.66 per share	0.01
XCUR Exicure	$500K	103.14	N/A	N/A	$1.12 per share	7.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	-$9.70M	-$3.82	N/A	∞	N/A	N/A	-219.60%	-82.03%	8/12/2025 (Estimated)

Latest XCUR, RAPT, GNFT, and SXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
6/27/2025	Q1 2025	XCUR Exicure	N/A	-$0.45	N/A	$0.49	N/A	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNFT GENFIT	0.08	1.23	1.23
RAPT Rapt Therapeutics	N/A	21.11	21.11
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
XCUR Exicure	N/A	2.91	2.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNFT GENFIT	2.24%
RAPT Rapt Therapeutics	99.09%
SXTC China SXT Pharmaceuticals	5.02%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
GNFT GENFIT	4.20%
RAPT Rapt Therapeutics	2.36%
SXTC China SXT Pharmaceuticals	3.95%
XCUR Exicure	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
XCUR Exicure	50	6.32 million	6.07 million	Not Optionable

XCUR, RAPT, GNFT, and SXTC Headlines

Recent News About These Companies

XCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatch

July 19, 2025 | marketwatch.com

Is Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?

June 30, 2025 | msn.com

Exicure Shares Up After Swing to Profit in 1Q

June 27, 2025 | marketwatch.com

Exicure, Inc. Reports First Quarter 2025 Financial Results

June 27, 2025 | businesswire.com

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025 | businesswire.com

Why Exicure Inc. (XCUR) Soared on Monday

April 22, 2025 | msn.com

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma

April 16, 2025 | pharmabiz.comP

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100

April 15, 2025 | pharmabiz.comP

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

April 14, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...

April 11, 2025 | gurufocus.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | investing.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | businesswire.com

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks

March 27, 2025 | investing.com

Exicure, Inc. Reports Full Year 2024 Financial Results

March 18, 2025 | gurufocus.com

Exicure secures Australian patent for cancer treatment

March 15, 2025 | investing.com

Exicure announces issuance of new patent in Australia

March 15, 2025 | markets.businessinsider.com

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

March 13, 2025 | gurufocus.com

Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm

January 27, 2025 | markets.businessinsider.com

Exicure announces purchase agreement with GPCR Therapeutics

January 24, 2025 | markets.businessinsider.com

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

January 22, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, RAPT, GNFT, and SXTC Company Descriptions

GENFIT NASDAQ:GNFT

$4.06 -0.01 (-0.25%)

As of 03:59 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Rapt Therapeutics NASDAQ:RAPT

$12.65 -1.29 (-9.25%)

Closing price 04:00 PM Eastern

Extended Trading

$13.10 +0.45 (+3.52%)

As of 07:50 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

China SXT Pharmaceuticals NASDAQ:SXTC

$1.62 -0.07 (-4.14%)

Closing price 03:59 PM Eastern

Extended Trading

$1.66 +0.04 (+2.78%)

As of 06:38 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Exicure NASDAQ:XCUR

$8.16 -0.22 (-2.63%)

Closing price 04:00 PM Eastern

Extended Trading

$8.16 0.00 (0.00%)

As of 06:55 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time